SYSTEMS AND METHODS FOR GEL-BASED NEUROMODULATION
Methods, devices and systems are described for gel-based modulation of neural tissue, including prevention of nerve regeneration and neuroma formation. The gel can be delivered to selected target locations within or proximate nerves, including interfascicularly and intrafascicularly. Gel delivery associated with an operative procedure for the treatment of pain and other indications is also disclosed.
1 . A method of modulating a nerve of a patient, comprising:
providing a urethane bond-containing hydrogel comprising a therapeutic agent;
identifying a target region associated with the nerve under imaging guidance; and
injecting the hydrogel into the target region.
2 . The method of claim 1 , wherein the target region comprises a region within the epineurium of the nerve.
3 . The method of claim 1 , wherein the target region comprises a region in between fascicles of the nerve.
4 . The method of claim 1 , wherein the target region is delivered in contact with the nerve perineurally.
5 . The method of claim 1 , wherein the hydrogel is adherent to the nerve for a period of 3 months or more.
6 . The method of claim 1 , wherein the target region comprises delivery under ultrasound guidance.
7 . The method of claim 1 , wherein the target region comprises multiple discrete fascicles of the nerve.
8 . The method of claim 1 , wherein the target region comprises perineurium.
9 . The method of claim 1 , wherein the target region comprises epineurium.
10 . The method of claim 1 , wherein the target region comprises endoneurium.
11 . The method of claim 1 , wherein following injecting the hydrogel into the target region, the hydrogel swells to a volume greater than the volume injected to compress nerve bundles.
12 . The method of claim 1 , further comprising at least partially ablating the nerve prior to injecting the hydrogel into the target region.
13 . The method of claim 1 , wherein the nerve comprises a peripheral nerve.
14 . The method of claim 1 , further comprising performing an operative procedure.
15 . The method of claim 12 , wherein the operative procedure comprises a total knee arthroplasty.
16 . The method of claim 1 , wherein the target region comprises one or more of the adductor canal, genicular nerves, a popliteal nerves (iPACK), the sciatic nerve, and the femoral nerve.
17 . The method of claim 1 , wherein the hydrogel comprises an anesthetic agent.
18 . The method of claim 1 , wherein the hydrogel comprises a neuromodulatory agent.
19 . The method of claim 1 , wherein the hydrogel comprises a neuroablative agent.
20 . The method of claim 1 wherein the agent is combined with an anesthetic.
21 . The method of claim 1 , wherein the hydrogel comprises ethanol.
22 . The method of claim 21 , wherein the ethanol comprises greater than 50% loading in the hydrogel.
23 . The method of claim 1 , wherein the gel has a porosity of less than about 50 μm.
24 . The method of claim 1 , wherein the gel has a porosity of less than about 20 μm.
25 . The method of claim 1 , wherein the gel comprises a biodegradable or bioerodable polymer susceptible to hydrolysis, enzymatic, or oxidative degradation.
26 . The method of claim 1 , wherein the gel is in situ forming.
27 . The method of claim 1 , wherein the gel comprises a multi-arm PEG-NHS ester.
28 . The method of claim 1 , wherein the gel comprises a hydrolytically degradable urethane bond.
29 . The method of claim 1 , wherein the gel comprises PEG-ester.
30 . The method of claim 1 , wherein the gel comprises saline.
31 . The method of claim 30 , wherein the polyethylene glycol comprises a blend of two multi-arm polyethylene glycols.
32 . The method of claim 31 , wherein the multi-arm polyethylene glycol comprises at least a 4-arm polyethylene glycol succinimidyl carbonate.